The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 16.93 — safe zoneOK
- Earnings-manipulation signal · Beneish M -2.26 — no flag raisedOK
- Earnings quality 94/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as UNITED THERAPEUTICS Corp reports it. History and quarterly detail are in the app.
- Tyvaso$1.9B
- Remodulin$526.8M
- Orenitram$496.9M
- Unituxin$226.8M
- Adcirca$30.0M
Latest filings
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-07-23
- 8-K · Company announcement2026-06-29
- 8-K · Company announcement2026-05-06
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about UNITED THERAPEUTICS Corp, every answer cited to the official filings🔒
- The Intelligence Brief — added when UNITED THERAPEUTICS Corp's brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.